Ready-Made immune cells take on blood cancers in early trial
NCT ID NCT07518329
First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 2 times
Summary
This early-phase study tests a new cell therapy called ALA-101 for people with CD19+ non-Hodgkin lymphoma or leukemia. The therapy uses donor immune cells that are specially designed to find and attack cancer cells. The main goals are to check safety and find the best dose, with about 46 adults expected to join.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Epworth HealthCare
Richmond, Victoria, 3121, Australia
Contact Email: •••••@•••••
-
Mater Misericordiae Ltd (MML)
Brisbane, Queensland, 4101, Australia
-
Royal Adelaide Hospital
Adelaide, South Australia, 5000, Australia
-
St. Vincent's Hospital
Sydney, New South Wales, 2010, Australia
-
The Alfred Hospital
Melbourne, Victoria, 3004, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune cells plus a checkpoint drug outsmart lymphoma?
- Can an immune booster outsmart brain lymphoma?
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a Triple-Drug combo wipe out Slow-Growing lymphomas?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?